In a small study involving seven patients with relapsed or refractory MM and an eGFR of 15–29 mL/min per 1.73 m2, CAR T-cell therapies directed at either BCMA alone or a combination of BCMA and CD19 demonstrated a 100% overall response rate and 100% renal response rates. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.